1800-272-662
Shopping Cart 0
countryflagAU
Login

Gyre Therapeutics Inc.

Healthcare US GYRE

8.3USD
0.18(2.22%)

Last update at 2026-03-11T14:53:00Z

Day Range

8.098.37
LowHigh

52 Week Range

3.1530.40
LowHigh

Fundamentals

  • Previous Close 8.12
  • Market Cap1501.69M
  • Volume40083
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -76.96500M -7.89400M -87.93300M -56.24100M -55.17800M
Minority interest -7.45300M -2.01200M - - -
Net income -92.93300M 2.30M -87.93300M -55.54200M -52.88700M
Selling general administrative 14.66M 17.37M 18.96M 16.18M 13.42M
Selling and marketing expenses 61.16M 54.24M 44.65M - -
Gross profit 108.81M -0.00400M -0.04200M 11.79M -43.85900M
Reconciled depreciation 1.11M 1.13M 1.93M - -
Ebit 114.92M -8.61100M -87.89400M -57.50800M -57.42300M
Ebitda 116.03M -52.15300M -87.60400M -57.37000M -57.27700M
Depreciation and amortization 1.11M -43.54200M 0.29M 0.14M 0.15M
Non operating income net other - - - - -
Operating income -67.23000M -8.61100M -87.89400M -57.37000M -57.27700M
Other operating expenses 94.24M 31.20M 95.23M 78.32M 57.28M
Interest expense - 0.72M 0.04M - -
Tax provision 8.52M 5.10M 6.17M - -
Interest income - 4.88M 0.38M - -
Net interest income 1.04M 0.73M 0.26M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 8.52M 0.35M -0.03900M -0.69900M -2.29100M
Total revenue 113.45M 0.79M 7.34M 20.95M -
Total operating expenses 89.60M 30.40M 87.85M 69.16M 57.28M
Cost of revenue 4.64M 0.80M 7.38M 9.16M 43.86M
Total other income expense net -97.22200M 0.72M -0.03900M 1.13M 2.10M
Discontinued operations - - - - -
Net income from continuing ops -85.48000M 4.31M 23.44M - -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 116.54M 709.59M 540.87M 94.85M 98.55M
Intangible assets 0.20M 161.25M 132.35M - -
Earning assets - - - - -
Other current assets 1.04M - - 6.84M 4.20M
Total liab 102.59M 85.12M 76.04M 18.78M 30.22M
Total stockholder equity -15.82800M 624.47M 464.83M 76.07M 68.34M
Deferred long term liab - - - - -
Other current liab 19.40M - - 9.22M 9.14M
Common stock 0.08M - - 0.02M 0.01M
Capital stock 0.08M 61.32M 61.32M - -
Retained earnings -85.53800M 283.04M 147.11M -314.76100M -258.52000M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 33.51M 163.42M 166.29M 30.36M 15.37M
Cash and equivalents - - - - -
Total current liabilities 20.05M 78.07M 65.63M 17.80M 28.90M
Current deferred revenue 0.08M - - 1.98M 15.00M
Net debt -33.10000M - - -28.71600M -13.56700M
Short term debt 0.21M - - 0.66M 0.48M
Short long term debt - - - - -
Short long term debt total 0.41M - - 1.64M 1.80M
Other stockholder equity 3.65M - - 390.80M 326.81M
Property plant equipment - - - - -
Total current assets 57.22M 333.90M 285.89M 89.51M 96.07M
Long term investments 23.43M 51.50M 0.00000M - -
Net tangible assets - - - - -
Short term investments - 10.60M 2.48M 48.99M 61.50M
Net receivables 16.84M 108.75M 64.06M 3.31M 15.00M
Long term debt - - - - -
Inventory 4.28M 42.64M 36.46M 0.00100M -
Accounts payable 0.35M 0.85M 1.60M 5.93M 4.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.45M - - 0.00500M 0.03M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.72M - - 0.53M 0.26M
Deferred long term asset charges - - - - -
Non current assets total 59.32M 375.69M 254.98M 5.34M 2.49M
Capital lease obligations 0.41M 4.99M 7.83M - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -19.76000M -13.81400M -8.19080M - -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 2.50M -45.01100M 49.55M 60.38M 0.33M
Change to operating activities - - - - -
Net income -85.48000M -8.24200M -87.93300M -56.24100M -55.17800M
Change in cash 8.33M -22.68100M 13.99M 14.99M -15.89400M
Begin period cash flow 25.18M 44.35M 30.36M 15.37M 31.26M
End period cash flow 33.51M 21.67M 44.35M 30.36M 15.37M
Total cash from operating activities 25.89M -33.09600M -83.75500M -55.04800M -43.61300M
Issuance of capital stock 2.50M 0.00000M - - -
Depreciation 1.11M 0.23M 0.29M 0.14M 0.15M
Other cashflows from investing activities - - - - -
Dividends paid - 45.03M 0.00000M - -
Change to inventory 1.75M -0.87900M 3.88M -3.04300M -0.49000M
Change to account receivables 1.40M 1.62M 1.50M 11.69M -15.00000M
Sale purchase of stock - - - - -
Other cashflows from financing activities 2.50M 0.02M 0.30M 0.43M 0.33M
Change to netincome - - - - -
Capital expenditures 8.59M 5.00M 0.84M 0.27M 0.06M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 7.46M -4.94500M 0.48M -2.57200M 8.21M
Stock based compensation 7.28M 13.37M 3.40M 3.63M 3.20M
Other non cash items 96.68M -21.48100M 3.89M 1.05M 11.42M
Free cash flow 17.31M -38.09400M -84.59400M -55.31500M -43.67700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GYRE
Gyre Therapeutics Inc.		 0.18 2.22% 8.30 - - 13.74 16.13 2.09 7.20
NVO
Novo Nordisk A/S		 0.16 0.41% 38.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.89 0.98% 494.28 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.71 0.48% 775.75 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Gyre Therapeutics Inc.

12770 High Bluff Drive, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Han Ying Ph.D. CEO & Director NA
Mr. Songjiang Ma President & Director NA
Ms. Ruoyu Chen Interim Chief Financial Officer 1970
Mr. Weiguo Ye Chief Operating Officer NA
Ms. Seline E. Miller CPA Senior Vice President of Finance 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.